The recent controversy surrounding c-kit+ cardiac stem cells and interruption of the CONCERT-HF (Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure) trial has significantly contributed to uncertainty regarding the clinical efficacy of this approach (39–45). The gene discussed is KIT; the disease is hydrops fetalis.